• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Transgenic Animals and Plants in Pharmaceutical Research and Manufacturing

$995.00 – $5,990.00

Clear
SKU: KLI1186400 Categories: Manufacturing & Packaging, Pharmaceuticals Market Research Pages: 204
  • Description
  • Table of Contents
  • Latest reports

Description

With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products.

As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry. One issue that is not debatable, though, is the high cost of manufacturing biopharmaceuticals. While biopharmaceuticals produced in bacterial or mammalian cell culture bioreactor facilities have proven to be very effective therapeutic agents, they are also among the most expensive drugs produced, and there is doubt that the current pricing models are sustainable regardless of these agents’ efficacy.

One way to address these concerns is through transgenics, which makes use of animals and plants to manufacture biopharmaceuticals. Mammalian, avian, and plant platforms for biomanufacturing can dramatically decrease costs of production, facilities and, scale-up. In the research realm, many scientists believe that the transgenic mouse and other transgenic species will help lead researchers to a biomedical revolution over the next decade.

This report provides a comprehensive analysis of the current status of the subsector of the biotechnology industry focused on animal and plant transgenics for biopharmaceutical production and research. The transgenic species and technologies involved in the production of human biopharmaceuticals are detailed, including an in-depth discussion of individual products currently in research and clinical trials. The report concentrates on the use of whole transgenic animals and plants as an alternative biomanufacturing method as opposed to traditional methods of microbial fermentation or mammalian cell culture.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Kalorama Information conducted interviews with key industry officials, consultants, scientists developing transgenic technology, and other individuals at university and private laboratories involved in transgenic research. These sources were the primary basis for information specifically relating to trends affecting the science of transgenics, and calculating the future revenues of this nascent biotechnology sector. Specific interviews with transgenic organizations company representatives included marketing directors, division managers, and product representatives.

Table of Contents

chapter one: Executive Summary

  • Introduction
    • Scope and Methodology
    • Transgenesis Development
    • Biopharmaceuticals Derived from Transgenic Sources
    • The Expanding Biopharmaceuticals Market
    • Manufacturing Biopharmaceuticals
    • The Commercial Transgenic Rodent Business
    • Transgenic Domestic Animals and Plants: An Alternative Biomanufacturing Method
    • Transgenic Expression Compared with Traditional Production Methods
    • Transgenic Animals
    • Protein Expression in Milk and Blood
    • Avian Transgenics
    • Animal-Derived Biopharmaceuticals in Research and Clinical Trials
    • Product Candidates Generated in Transgenic Cattle
    • Product Candidates Generated in Transgenic Goats
    • Product Candidate Generated in Transgenic Rabbits
    • Avian-Derived Products in Research and Development
    • Transgenics Plants
    • Capacity Comparison: Plants with Other Transgenic Systems
    • Major Advantages of Plant-Derived Proteins
    • Plant-Derived Biopharmaceuticals in Research and Clinical Trials
    • Transgenic Arabidopsis
    • Transgenic Corn
    • Transgenic Lemna
    • Transgenic Tobacco
    • Projected Market for Transgenically Produced Biopharmaceuticals
  • chapter Two: The Development and Manufacture of Transgenically Produced Biopharmaceuticals
    • Molecular Biology and Genetic Engineering
    • Biopharmaceuticals Derived from Transgenic Sources
    • The Expanding Biopharmaceuticals Market
    • Manufacturing Biopharmaceuticals
    • Cell-Based Manufacturing Systems Are Costly and Inefficient
    • Improving Volumetric Productivity
    • Transgenic Domestic Animals and Plants: An Alternative Biomanufacturing Method
    • Domestic Animals as Bioreactors
    • Proteins Produced in Transgenic Chickens
    • Plants as Bioreactors for Biopharmaceutical Production
    • Public Perceptions of Transgenic Animals and Plants
    • Biotechnology-Focused Legislation
  • chapter Three: Transgenic Rodents Developed for Research and Biopharmaceutical Production
    • Producing Transgenic Mice
    • Pronuclear Microinjection
    • Knockout Gene Technology
    • Knock-in Gene Technology
    • Embryonic Stem Cell Techniques
    • Somatic Nuclear Transfer
    • Value of Transgenic Rodents
    • Rodent Models of Human Disease
    • Transgenic Models Characterized for Human Diseases
    • Rodent Antibodies as Therapeutic Agents
    • Types of Rodent-Derived Antibodies
    • Murine Antibody
    • Chimeric Antibody
    • Humanized Antibody
    • Fully Human Antibody
    • Manufacturing Biopharmaceuticals
    • Phage Display: A Competing Technology
    • The Commercial Transgenic Rodent Business
    • Commercial Sale of Transgenic Rodents
    • Commercial Rodent Model Market
    • Leading Companies Providing Commercial Rodent Models
    • Commercial Rodent Model Market Trends
  • chapter four: Transgenically Produced Biopharmaceuticals in Animal and Avian Platforms
    • Introduction
    • Applications of Transgenesis
    • Transgenic Domestic Animals as Bioreactors
    • Transgenic Domestic Animal as a Model for Disease
    • Transgenic Mammals
    • Transgenic Protein Expression Compared with Traditional Production Methods
    • Protein Expression in Milk and Blood
    • Key Characteristics of Transgenic Mammals
    • General Management Practices for Specialized Farms
    • Relevant Regulatory Agencies and Regulatory Authority
    • Animal-Derived Biopharmaceuticals in Research and Clinical Trials
    • Types of Transgenic Mammals and Their Product Candidates
    • Transgenic Cattle
    • Transgenic Goats
    • Transgenic Rabbits
    • Transgenic Sheep
    • Transgenic Swine
    • Avian Transgenics
    • Potential for Reduced Capital Outlay
    • Large Amount of Protein Generated Quickly
    • Ease of Scale-up
    • Glycosylation
    • Contained and Controlled Environment
    • Avian Transgenic Technology
    • Anticancer Antibody Expressed in Chicken Eggs
    • Monoclonal Antibodies Produced in Chickens
    • Avian-Derived Products in Research and Development
  • chapter five: Transgenically Produced Biopharmaceuticals Manufactured in Plant Platforms
    • Introduction
    • History of the Production rDna Proteins in Plants
    • Transgenic Plant Technology
    • Agrobacterium Tumefaciens-Mediated Transformation System
    • Particle Bombardment Transformation System
    • Future Developments in Transgenic Technology
    • Transgenic Plants Come of Age
    • The Benefits of Producing Biopharmaceuticals in Plants
    • Potential Risks Associated with Producing Biopharmaceuticals in Plants
    • Contamination of Non-Transgenic Crops Intended for Human Consumption
    • The Containment Challenge
    • Field Testing of PMPs in the U.S.
    • Genetic Use Restriction Technologies
    • Plant-Derived Biopharmaceuticals in Research and Clinical Trials
    • Transgenic Arabidopsis
    • Transgenic Corn
    • Transgenic Lemna
    • Transgenic Tobacco
  • chapter six: Projected Market for Transgenically Produced BioPharmaceuticals Manufactured in Plant and Animal Platforms
    • Introduction
    • Biopharmaceutical Market Maturing Rapidly
    • Transgenic Animal and Plant Factories: An Emerging Biotechnology Sector
    • Transgenic Animal and Plant Bioreactors: An Alternative Production System for Biopharmaceuticals
    • Projected Market for Transgenically Produced Biopharmaceuticals
    • Projected Sales of Transgenically Manufactured Products Closest to Market
    • ATryn
    • CaroRX
    • rhC1NH
  • chapter Seven: Company Profiles
    • Abgenix, Inc.
    • History and Lines of Business
    • Corporate Strategies
    • Transgenic Products and Product Candidates
    • Financial Information
    • Avigenics, Inc
    • History and Lines of Business
    • Corporate Strategy
    • Transgenic Technology and Product Candidates
    • Financial Information
    • Biolex Therapeutics, Inc.
    • History and Lines of Business
    • Corporate Strategies
    • Transgenic Technology
    • Financial Information
    • Charles River Laboratories, Inc.
    • History and Lines of Business
    • Corporate Strategy
    • Research Models and Services Business
    • Financial Information
    • GTC Biotherapeutics, Inc,.
    • History and Lines of Business
    • Transgenic Technology and Product Candidates
    • Financial Information
    • Hematech LLC
    • History and Lines of Business
    • Transgenic Technology
    • Antibodic Resistant Infections
    • Immune Deficiencies
    • Other Applications
    • Financial Information
    • Large Scale Biology Corporation
    • History and Lines of Business
    • Corporate Strategies
    • Transgenic Technology and Product Candidates
    • Financial Information
    • Medarex, Inc.
    • History and Lines of Business
    • Corporate Strategies
    • Transgenic Technology and Product Candidates
    • Financial Information
    • Origen Therapeutics
    • History and Lines of Business
    • Transgenic Technology
    • Financial Information
    • Pharming Group NV
    • History and Lines of Business
    • Transgenic Technology and Product Candidates
    • Financial Information
    • Phytomedics, Inc.
    • History and Lines of Business
    • Corporate Strategy
    • Transgenic Technology
    • Financial Information
    • Planet Biotechnology Inc.
    • History and Lines of Business
    • Transgenic Technology and Product Candidates
    • Financial Information
    • ProdiGene, Inc.
    • History and Lines of Business
    • Corporate Strategy
    • Transgenic Technology and Product Candidates
    • Financial Information
    • SemBioSys Genetics, Inc.
    • History and Lines of Business
    • Transgenic Technology and Product Candidates
    • Financial Information
    • Taconic Farms, Inc.
    • History and Lines of Business
    • Research Models and Services Business
    • Financial Information
    • Ventria Bioscience
    • History and Lines of Business
    • Corporate Strategy
    • Transgenic Technology and Product Candidates
    • Financial Information
    • Viragen International, Inc.
    • History and Lines of Business
    • Transgenic Technology
    • Financial Information
    • Xenogen Corporation
    • History and Lines of Business
    • Transgenic Technology and Products
    • IVIS Imaging Systems and Living Image Software
    • Bioware—Light-Producing Cells and Microorganisms
    • LPTA Animal Models
    • Financial Information
  • Appendix A: Company Directory
  • Appendix B: Biopharmaceuticals Produced in Transgenic Animal and Plant Platforms in Research and Clinical Trials
  • List of Exhibits
  • chapter one: Executive Summary
    • Table 1-1: Selection of Monoclonal Antibodies on the Market and in Advanced Clinical Trials, Derived from Transgenic Rodents
    • Table 1-2: Biopharmaceuticals Approved in the United States and the European Union in 2004
    • Figure 1-1: Worldwide Commercial Rodent Model Market Share
    • Table 1-3: Selected Companies Focused on Transgenic Biopharmaceutical Production, 2005
    • Table 1-4: Selected Avian-Derived Biopharmaceuticals in Research and Development
    • Table 1-5: A Comparison of Capacity of Transgenic Production Systems (Productivity and Volume Required for 1,000 Kg of Production)
    • Table 1-6: Projected Market for Biopharmaceuticals Produced in Animal and
    • Plant Platforms 2006-2015
  • chapter Two: The Development and Manufacture of Transgenically Produced Biopharmaceuticals
    • Table 2-1: Biopharmaceuticals Approved in the United States and the European Union in 2004
    • Table 2-2: Approval Projections for Therapeutic Monoclonal
    • Antibodies, 2005-2008
    • Table 2-3: Selected Companies Focused on Transgenic Biopharmacutical Production, 2005
    • Table 2-4: Selected Companies Focused on Plant-Manufactured
    • Pharmaceuticals
  • chapter Three: Transgenic Rodents Developed for Research and Biopharmaceutical Production
    • Table 3-1: Selection of Monoclonal Antibodies on the Market or in Advanced Clinical Trials, Derived from Transgenic Rodents
    • Figure 3-1: Evolution of Antibody Technologies
    • Table 3-2: Worldwide Commercial Rodent Model Market 2001-2010
    • Figure 3-2: Worldwide Commercial Rodent Model Market Share
  • chapter four: Transgenically Produced Biopharmaceuticals in Animal and Avian Platforms
    • Table 4-1: Selection of Proteins Expressed in Transgenic Domestic Animals
    • Table 4-2: Key Characteristics of Transgenic Animals Used in Biopharmaceutical Production
    • Table 4-3: Selected Animal-Derived Biopharmaceuticals in Research and
    • Clinical Trials
    • Table 4-4: Selected Avian-derived Biopharmaceuticals in Research and
    • Development
  • chapter five: Transgenically Produced Biopharmaceuticals Manufactured in Plant Platforms
    • Table 5-1: History of Pharmaceutical Proteins Produced In Transgenic
    • Plants
    • Table 5-2: A Comparison of Capacity of Transgenic Production Systems (Productivity and Volume Required for 1,000 Kg of Production)
    • Table 5-3: A Comparison of Pharmaceutial Expession Systems
    • Table 5-4: Major Advantages of Plant Derived Proteins
    • Figure 5-1: Timeline for Key Deliverables in a Corn Seed System
    • Table 5-5: Number of Field Testing Permits by APHIS by Species and
    • Product Type 1991-2004 cumulative
    • Table 5-6: Plant-Derived Biopharmaceuticals in Research and Clinical
    • Trials
  • chapter six: Projected Market for Transgenically Produced BioPharmaceuticals Manufactured in Plant and Animal Platforms
    • Figure 6-1: Worldwide Distribution of Competitors by Geography
    • Table 6-1: Transgenically Produced Biopharmaceuticals Pending Approval or in Clinical Phase III and II
    • Table 6-2: Projected Market for Biopharmaceuticals Produced in Animal and
    • Plant Platforms 2006-2015
  • chapter Seven: Company Profiles
    • Table 7-1: Phase III and Phase II Product Candidates in Clinical Development
    • Figure 7-2: Phase I and Selected Preclinical Product Candidates

 

    Biopharmaceutical Contract Manufacturing Organization (BCMO) Market, 2022
    August 2, 2022
    100 Companies in Contract Pharmaceutical Research – White Paper
    March 27, 2018
    Biopharmaceutical Contract Manufacturing (BCMO) Market – by Type of Service, by Organization and by Region
    November 29, 2017
    Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, Forecasts to 2018, 6th Edition
    April 30, 2014

Related products

  • Placeholder image

    Market for Rx-to-OTC Switches, 3rd Edition, The

    $2,625.00 – $5,250.00
  • Placeholder image

    Outsourcing in Drug Development – The Contract Research Market from Preclinical to Phase III

    $3,500.00 – $7,000.00
  • Placeholder image

    U.S. Market for OTC Diet Aids, The

    $3,000.00 – $6,000.00
  • Placeholder image

    Cardiovascular Disease: The 45 Market in the United States for Drugs and Medical Devices

    $2,995.00 – $5,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
The U.S. Market for Over-the-Counter Anti-InfectivesThe Worldwide Market for Prescription Dermatological Drugs, 5th Edition
Scroll to top